Cartesian Therapeutics, Inc. (RNAC) key performance indicators and operating metrics (6 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Grant Revenue | 452K | FY2025-Q3 |
| Approximate Number of Participants in Phase 3 AURORA Trial | 100.00 | FY2025-Q3 |
| Average Reduction in Myasthenia Gravis Activities of Daily Living Score at Month 12 | 4.80 ratio | FY2025-Q2 |
| Average Reduction in Myasthenia Gravis Activities of Daily Living Score at Month 12 (Without Prior Biologic Therapies) | 7.10 ratio | FY2025-Q2 |
| Patients Maintaining Minimum Symptom Expression at Month 12 (Without Prior Biologic Therapies) | 57.00 percent | FY2025-Q2 |
| Participants With Clinically Meaningful Response at Month 12 (Myasthenia Gravis Activities of Daily Living Reduction of at Least 2 Points) (Evaluable Participants) | 83.00 percent | FY2025-Q1 |
Back to RNAC overview · RNAC earnings · RNAC holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.